NervGen Pharma (NGEN) Corporate presentation summary

Market opportunity and unmet need

• Chronic tetraplegia affects ~149,000 adults in the U.S., with no approved pharmacologic treatments and a significant economic burden, up to $8.3M lifetime cost per patient.

• NVG-291 targets a >$20B market, aiming to be the first approved drug for chronic tetraplegia, with a potential multi-billion dollar annual revenue at 10% market penetration.

• Hand function restoration is the top priority for patients, directly impacting independence and quality of life.

Scientific rationale and mechanism

• NVG-291 is the first drug candidate to directly target the CSPG-PTPO pathway, overcoming the primary biological barrier to nervous system repair.

• Preclinical studies in rodent models showed NVG-291 restored neuronal growth and significant functional recovery after spinal cord injury.

• Efficacy demonstrated across more than 15 models of nervous system damage, supporting broad therapeutic potential.

Clinical evidence and efficacy

• In the CONNECT SCI Phase 1b/2a study, NVG-291 outperformed placebo in hand function (GRASSP QtP), exceeding the clinically meaningful threshold by 85% at week 12 and 120% at week 16.

• Statistically significant improvements were observed in upper-body corticospinal signaling and reduction of maladaptive reticulospinal hyperactivity.

• NVG-291 subjects showed up to 5x the clinically meaningful threshold in functional hand use, with effects persisting after treatment cessation.

• Biomechanical gait analysis confirmed genuine recovery of walking function, with all NVG-291 subjects outperforming placebo across coordination, effort, and posture.